EN | UA
EN | UA

Help Support

Back

Benefit of tailored TBT based on past medication history for H. pylori eradication

Tailored triple plus bismuth therapy Tailored triple plus bismuth therapy
Tailored triple plus bismuth therapy Tailored triple plus bismuth therapy

A randomized trial was conducted to examine if tailored triple plus bismuth therapy (TBT) can attain greater elimination rates than empiric TBTs based on past antibiotic history.

See All

Key take away

For first-line H. pylori management, tailored triple plus bismuth therapy on the basis of prior antibiotic use can yield greater elimination rates than empiric triple plus bismuth therapy.

Background

A randomized trial was conducted to examine if tailored triple plus bismuth therapy (TBT) can attain greater elimination rates than empiric TBTs based on past antibiotic history.

Method

Overall, 800 subjects who had never received therapy were divided into 4 arms at random receiving Clarithromycin-, Levofloxacin- or Metronidazole-containing empiric TBT and tailored TBT (Levofloxacin and Clarithromycin selected on the basis of prior Quinolones and Macrolides history). Analysis of correlations between prior drug use and elimination or resistance rates was done.

Result

In intention-to-treat (89.5%, 80.8%, 81.5%, 81.5%) and per-protocol (95.1%, 86.7%, 86.5%, 87.8%) assessment, the elimination rates of tailored TBT were considerably greater when compared to Clarithromycin-, Levofloxacin-, and Metronidazole-containing empiric TBT.

Subjects who had previously taken Macrolides, Quinolones, or Nitroimidazoles had substantially greater rates of resistance to the corresponding Clarithromycin, Levofloxacin, or Metronidazole than subjects without past medication history, and the elimination rates of corresponding Levofloxacin- or Clarithromycin-containing empiric TBT was substantially lower.

Conclusion

Tailored TBT can yield greater H. pylori elimination rates than empiric TBT based on prior antibiotic use.

Source:

Digestive and Liver Disease

Article:

Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori elimination: A randomized trial

Authors:

Zhiqiang Song et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: